← back to search

Tarekegn Geberhiwot

University of Birmingham · GB
Area of research
Physiology · Genetics
Research interest
Research interests include Medicine, Internal medicine, Cardiology, Adverse effect, Fabry disease, and Disease.
h-index
citations
1,100
works
12
NIH funding
primary concept
email

Recent publications

Interim analyses of a first-in-human phase 1/2 mRNA trial for propionic acidaemia
Nature 2024cited by 114position: middledoi
Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study
Journal of Medical Genetics 2023cited by 42position: middledoi
Venglustat, an orally administered glucosylceramide synthase inhibitor: Assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study
Molecular Genetics and Metabolism 2022cited by 48position: middledoi
Consensus clinical management guidelines for Alström syndrome
Orphanet Journal of Rare Diseases 2020cited by 103position: lastdoi
Myocardial Edema, Myocyte Injury, and Disease Severity in Fabry Disease
Circulation Cardiovascular Imaging 2020cited by 87position: middledoi
The myocardial phenotype of Fabry disease pre-hypertrophy and pre-detectable storage
European Heart Journal - Cardiovascular Imaging 2020cited by 75position: middledoi
Myocardial Storage, Inflammation, and Cardiac Phenotype in Fabry Disease After One Year of Enzyme Replacement Therapy
Circulation Cardiovascular Imaging 2019cited by 74position: middledoi
Consensus clinical management guidelines for Niemann-Pick disease type C
Orphanet Journal of Rare Diseases 2018cited by 287position: middledoi
Global longitudinal strain, myocardial storage and hypertrophy in Fabry disease
Heart 2018cited by 68position: middledoi
Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practice
EP Europace 2017cited by 130position: middledoi
A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease
Orphanet Journal of Rare Diseases 2017cited by 38position: middledoi
Impact of elosulfase alfa in patients with morquio A syndrome who have limited ambulation: An open‐label, phase 2 study
American Journal of Medical Genetics Part A 2016cited by 34position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Richard P. Steeds · Investigators Research Group (United States)6 papers (2017–2020)James Moon · National Medical Center5 papers (2017–2020) · 5 papers (2017–2020)Rebecca Kozor · The University of Sydney5 papers (2017–2020)Ravi Vijapurapu · University of Birmingham4 papers (2018–2020)Uma Ramaswami · Ludwig-Maximilians-Universität München4 papers (2018–2020)João B. Augusto · Instituto de Investigação Agrária de Moçambique4 papers (2018–2020)Michel Tchan · Westmead Hospital3 papers (2018–2020)Shanat Baig · University of Birmingham3 papers (2017–2020)Gabriella Captur · Royal Free London NHS Foundation Trust3 papers (2019–2020)Kristopher Knott · St Bartholomew's Hospital3 papers (2019–2020)Eugen Mengel · Johannes Gutenberg University Mainz3 papers (2016–2018) · 3 papers (2019–2020) · 2 papers (2020–2020)Sabrina Nordin · University of Glasgow2 papers (2017–2018)Stefania Rosmini · King's College - North Carolina2 papers (2018–2020)Christian J. Hendriksz · University of Manchester2 papers (2016–2018)Boyang Liu · University Hospitals Birmingham NHS Foundation Trust2 papers (2017–2018)Michael Mauer · Dartmouth College1 papers (2022–2022)Paul Harmatz · University of California, San Francisco1 papers (2016–2016)